All Stories

  1. Case Series Evaluating the Relationship of SGLT2 Inhibition to Pulmonary Artery Pressure and Non-Invasive Cardiopulmonary Parameters in HFpEF/HFmrEF Patients—A Pilot Study
  2. SIGNed explanations: Unveiling relevant features by reducing bias
  3. Rising and Falling High‐Sensitivity Cardiac Troponin in Diagnostic Algorithms for Patients With Suspected Myocardial Infarction
  4. Personalized diagnosis in suspected myocardial infarction
  5. Hemodynamic markers of pulmonary vasculopathy for prediction of early right heart failure and mortality after heart transplantation
  6. Outcomes After Early Postoperative Myocardial Infarction Due to Graft Failure in Patients Undergoing Coronary Artery Bypass Grafting
  7. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension
  8. Regional extracellular volume within late gadolinium enhancement-positive myocardium to differentiate cardiac sarcoidosis from myocarditis of other etiology: a cardiovascular magnetic resonance study
  9. Right Ventricular Strain by Magnetic Resonance Feature Tracking Is Largely Afterload-Dependent and Does Not Reflect Contractility: Validation by Combined Volumetry and Invasive Pressure Tracings
  10. Presepsin Predicts 1-Year All-Cause Mortality Better Than N-Terminal Pro-B-Type Natriuretic Peptide in Patients Undergoing Transcatheter Aortic Valve Implantation
  11. Gdf-15 and Soluble St2 As Biomarkers of Right Ventricular Dysfunction in Pulmonary Hypertension
  12. Exercise MR-proANP unmasks latent right heart failure in CTEPH
  13. Use of serial changes in biomarkers vs. baseline levels to predict left ventricular remodelling after STEMI
  14. Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension
  15. Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy
  16. A conceptual framework for establishing trust in real world intelligent systems
  17. Osteopontin and Galectin-3 As Biomarkers of Maladaptive Right Ventricular Remodeling In Pulmonary Hypertension
  18. A proposal for implementation of the chest pain unit model in Greece
  19. Association Between Primary Coronary Slow-Flow Phenomenon and Epicardial Fat Tissue
  20. An Experiment Environment for Definition, Training and Evaluation of Electrocardiogram-Based AI Models
  21. CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension
  22. Detecting myocardial scar using electrocardiogram data and deep neural networks
  23. Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
  24. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension
  25. Pregnancy-associated plasma protein A – a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension?
  26. The adipokine fatty-acid binding protein 4 and cardiac remodeling
  27. Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions – Comparison of uremic, hypertensive and hypertrophic cardiomyopathy
  28. SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension
  29. Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction
  30. High-Content Immunophenotyping and Hierarchical Clustering Reveal Sources of Heterogeneity and New Surface Markers of Human Blood Monocyte Subsets
  31. Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes
  32. Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA
  33. GDF-15 as a risk stratification biomarker for cardiovascular disease
  34. Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction
  35. Prognostic performance of the ESC SCORE and its German recalibrated versions in primary and secondary prevention
  36. Impact of Vascular Function on Maximum Power Output in Elite Handball Athletes
  37. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction
  38. Identification of acute myocardial infarction in elderly patients using optimized highly sensitive troponin I thresholds
  39. Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
  40. Troponinwerte und der akute Myokardinfarkt
  41. Bone marrow and plasma FGF‐23 in heart failure patients: novel insights into the heart–bone axis
  42. Identification and regulation of the long non-coding RNA Heat2 in heart failure
  43. High-sensitivity cardiac troponin assays: finally ready for prime time?
  44. Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease
  45. Right bundle branch block in patients with suspected myocardial infarction
  46. Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease
  47. Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis
  48. N-terminal pro–B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
  49. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs
  50. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation
  51. Troponin I Assay for Identification of a Significant Coronary Stenosis in Patients with Suspected Acute Myocardial Infarction and Wide QRS Complex
  52. Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain
  53. Influence of hypothermia and subsequent rewarming upon leukocyte-endothelial interactions and expression of Junctional-Adhesion-Molecules A and B
  54. Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model
  55. Strategies to overcome misdiagnosis of type 1 myocardial infarction using high sensitive cardiac troponin assays
  56. Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay
  57. Estimation of Values below the Limit of Detection of a Contemporary Sensitive Troponin I Assay Improves Diagnosis of Acute Myocardial Infarction
  58. Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease
  59. Assessment of microRNAs in patients with unstable angina pectoris
  60. From heart to toe: Heart's contribution on peripheral microRNA levels
  61. Dialyse- und Ultrafiltrationsverfahren bei kardio-renalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. und der Deutschen Gesellschaft für Nephrologie e.V.
  62. Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction
  63. Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study
  64. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis
  65. Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay
  66. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population
  67. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease
  68. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application
  69. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study
  70. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation
  71. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain
  72. Prognostic Information of Glycogen Phosphorylase Isoenzyme BB in Patients With Suspected Acute Coronary Syndrome
  73. Diagnostic and Prognostic Performance of Myeloperoxidase Plasma Levels Compared With Sensitive Troponins in Patients Admitted With Acute Onset Chest Pain
  74. Cardiac troponin determination in the diagnosis of acute myocardial infarction
  75. Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction
  76. Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome
  77. Midregional Proadrenomedullin for Prediction of Cardiovascular Events in Coronary Artery Disease: Results from the AtheroGene Study
  78. Reduktion der stationären Verweildauer bei Patienten mit akutem Koronarsyndrom durch Einrichtung einer Chest Pain Unit
  79. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie
  80. A Genome-Wide Association Study Identifies LIPA as a Susceptibility Gene for Coronary Artery Disease
  81. Making it More Sensitive
  82. Novel biomarkers in evaluation of acute coronary syndrome
  83. Tako-Tsubo syndrome: dying of a broken heart?
  84. Distribution and Categorization of Left Ventricular Measurements in the General Population
  85. Patientenzufriedenheit beim akuten Koronarsyndrom
  86. Copeptin Improves Early Diagnosis of Acute Myocardial Infarction
  87. Improved outcome in acute coronary syndrome by establishing a chest pain unit
  88. Rolle von Biomarkern zur Risikostratifizierung in der Prävention kardiovaskulärer Erkrankungen
  89. Entwicklung der Chest-Pain-Units in Deutschland
  90. Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction
  91. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study
  92. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
  93. Chest Pain Unit (CPU): erste Erfahrungen in Mainz
  94. Color Doppler Indices of Renal Allografts Depend on Vascular Stiffness of the Transplant Recipients